Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05194839Phase 2Terminated

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Role: lead

NCT05348681Phase 2Terminated

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Role: lead

NCT05448391Phase 2Withdrawn

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Role: lead

NCT03988335Phase 2Completed

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Role: lead

NCT05023811Phase 1Completed

A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects

Role: lead

NCT04105959Phase 1Completed

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Role: lead

All 6 trials loaded